文献速递认知障碍与痴呆

EOAD特征性萎缩可预测早发性MCI向痴呆进展

EOAD-Signature Atrophy Predicts Dementia in Early-Onset MCI due to Alzheimer Disease: An MRI-Based Prognostic Biomarker.
PubMed 文献 · Neurology · 2026-08-26

本研究基于纵向早发性阿尔茨海默病研究(LEADS)队列,纳入130例生物标志物支持的早发性AD所致MCI患者和97例认知正常对照,评估基线EOAD特征区皮层萎缩对痴呆进展的预测价值。Cox模型显示,基线EOAD特征区萎缩负担每增加1个标准差,痴呆进展风险比为1.24(95%CI 1.13-1.37;p<0.002),且在临床严重度基础上显著改善模型拟合(ΔAIC=-4.5;似然比检验p=0.011)。

要点

  • 基线EOAD特征区萎缩越重,早发性MCI向痴呆进展越快(HR=1.24/1-SD)。
  • EOAD特征区萎缩可提供超越基线临床严重度的预后信息。
  • 支持该MRI指标用于个体化预后评估和临床试验分层。

核心结论

  • 基线EOAD特征区皮层萎缩可预测早发性AD所致MCI向痴呆的进展,并提供超越基线临床严重度的预后信息。

研究设计与样本

  • 多中心自然史纵向早发性阿尔茨海默病研究(LEADS)队列,纳入130例生物标志物支持的早发性AD所致MCI患者(平均年龄59.6±4.1岁;49%女性)和97例认知正常对照(平均年龄56.9±6.0岁;64%女性)。

主要发现

  • 基线EOAD特征区萎缩负担每增加1个标准差,痴呆进展风险比为1.24(95%CI 1.13-1.37;p<0.002)。
  • 将EOAD特征区萎缩负担加入包含基线临床严重度的模型后,模型拟合显著改善(ΔAIC=-4.5;似然比检验p=0.011)。

临床怎么用

  • 可将基线EOAD特征区萎缩作为MRI预后生物标志物,辅助早发性MCI患者的个体化预后评估和临床试验分层。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Early-onset Alzheimer disease (EOAD) is associated with substantial variability in clinical progression, and reliable biomarkers to predict the transition from mild cognitive impairment (MCI) to dementia remain limited. Structural MRI measures have demonstrated prognostic value in late-onset Alzheimer disease, but their utility for predicting progression in EOAD is less well understood. The goal was to examine whether baseline cortical atrophy predicts progression to dementia in patients with MCI because of EOAD. METHODS: This study included a well-characterized cohort of patients with EOAD enrolled in the large multisite natural history Longitudinal Early-Onset Alzheimer's Disease Study. Participants underwent standardized clinical assessments and structural MRI at baseline. Participants were aged between 40 and 64 years with biomarker-supported sporadic EOAD at the MCI stage. Cortical atrophy was measured within the EOAD-signature, a set of predominantly parieto-temporal regions showing greater atrophy in EOAD than in controls. Clinical severity was measured with the global Clinical Dementia Rating. Cox proportional hazards models estimated the association between baseline EOAD-signature atrophy burden and the hazard of progression to dementia over time. We evaluated whether EOAD-signature atrophy improved prognostic performance beyond baseline clinical severity using likelihood ratio tests, Akaike Information Criterion (AIC), and Harrell concordance index. RESULTS: A total of 130 patients with MCI due to EOAD (mean age 59.6 ± 4.1 years; 49% female) and 97 cognitively normal controls (mean age 56.9 ± 6.0 years; 64% female) were included. Greater baseline atrophy within the EOAD-signature predicted faster progression to dementia (hazard ratio [HR] = 1.24 per 1-SD increase in atrophy; 95% CI 1.13-1.37; p < 0.002). Adding EOAD-signature atrophy burden to a model including baseline clinical severity significantly improved model fit (ΔAIC = -4.5; likelihood ratio test p = 0.011). DISCUSSION: Baseline cortical atrophy within the EOAD-signature predicts progression from MCI to dementia in EOAD and provides prognostic information beyond baseline clinical severity. These findings support the potential value of EOAD-signature atrophy as an MRI-based biomarker for individualized prognostication and clinical trial stratification.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Paranhos T, Katsumi Y, Brickhouse MJ, et al. EOAD-Signature Atrophy Predicts Dementia in Early-Onset MCI due to Alzheimer Disease: An MRI-Based Prognostic Biomarker. Neurology. 2026. PMID: 42647766. doi:10.1212/WNL.0000000000218519

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。